At Asphalion, we join this year’s campaign by recognizing that every person’s journey with cancer is different, yet we are united in our shared commitment to advance people‑centered care and improved outcomes for all.
We proudly contribute to the fight against cancer through our regulatory expertise, helping ensure the safe and efficient development of innovative therapies that meet the needs of patients and their communities, fos instance as part of the EU-funded PragmaTIL project, where we are in charge of the regulatory activities. The PragmaTIL project focuses on optimizing Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) to enhance cancer treatment in academic hospitals. By reducing the treatment-related toxicities of high-dose interleukin-2 (HD-IL-2) while maintaining efficacy, PragmaTIL aims to improve patient outcomes and expand clinical implementation.
Learn more about PragmaTIL: www.pragmatil.eu
Contact us at: [email protected]
Let’s all join the movement to put people at the centre of cancer care!
